立即登录 | 免费注册
全部学科 | 内科学 | 心血管病学 | 内分泌学与糖尿病 | 神经病学 | 消化病学 | 呼吸病学 | 肿瘤学 | 妇产科学 | 骨科学
疾病中心： 高血压 | 冠心病 | 心力衰竭 | 心律失常 | 脂肪性肝病 | 糖尿病 | 卒中 | 慢性阻塞性肺病 | 子宫内膜异位症 | 乳腺癌 | 肺癌 | 结直肠癌 | 器官移植
Loading
当前位置：期刊中心 > 中国作者重要发表 > 文摘导读

灯盏花制剂治疗急性脑梗死

Dengzhanhua preparations for acute cerebral infarction
Cao W., Liu W., Wu T., Zhong D., Liu G.   |   2009/5/29 18:39:20 
Cochrane Database of Systematic Reviews, 2008   |   Volume 0, Issue 4  |   打印| 推荐给好友
上一篇: 中药三七治疗急性缺血性卒中
下一篇: 中草药治疗急性支气管炎
Background: Dengzhanhua preparations are widely used in China. Many controlled trials have been undertaken to investigate the efficacy of dengzhanhua preparations in the treatment of acute cerebral infarction. Objectives: To assess whether dengzhanhua preparations are effective and safe at improving outcomes in patients with acute cerebral infarction. Search strategy: We searched the Cochrane Stroke Group Trials Register (last searched October 2007), the Chinese Stroke Trials Register (last searched June 2006), the trials register of the Cochrane Complementary Medicine Field (last searched June 2006), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, Issue 2 2006), MEDLINE (1966 to June 2006), EMBASE (1980 to June 2006), AMED (the Allied and Complementary Medicine Database, 1985 to June 2006), the China Biological Medicine Database (CBM-disc, 1979 to June 2006), and Chinese Knowledge Infrastructure (CNKI,1994 to October 2007). We also searched the reference lists of relevant articles. Selection criteria: Randomised and quasi-randomised controlled clinical trials of dengzhanhua preparations regardless of duration, dosage and route of administration in patients with confirmed acute cerebral infarction. Data collection and analysis: Two review authors independently applied the inclusion criteria, assessed trial quality, and extracted the data. Main results: We included nine trials, all conducted in China, involving 723 participants. Themethod of randomisation and concealment was poorly described. The included trials compared dengzhanhua injection plus routine therapy with routine therapy alone. Patients were enrolled up to one week after the onset of stroke. No trials reported data on the pre-specified primary or secondary outcomes. In a post-hoc comparison of dengzhanhua injection plus routine therapy versus routine therapy alone, dengzhanhua injection showed a statistically significant benefit on the outcome 'marked neurologic improvement' (relative risk 1.53; 95% confidence interval 1.36 to 1.72). No serious adverse effects were reported. Authors' conclusions: Due to the generally low methodological quality and small sample size of the included trials in this systematic review, we could not draw a firm conclusion. Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Correspondence Address: Liu, G.; Department of Evidence-Based Medicine and Clinical Epidemiology, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, Sichuan, 610041, China; email: ceuliu@hotmail.com 
关键词:

请登录后发表评论，点击此处登录。

慢性心衰诊治：规范中求突破
黄峻
2012-2-1
南京医科大学第一附属医院
房颤治疗：手段渐趋丰富 新型治疗药物不断涌现 非药物治疗备受关注
马长生
2012-2-1
首都医科大学附属北京安贞医院
注重老年人群特征 优化管理

刘梅林
2012-2-1
北京大学第一医院老年内科

 
相关文章

关注糖尿病，聚焦GLP-1！案例征集大赛
时间：2011-3~~2011-11
由中国医师协会主办、礼来国际贸易（上海）有限公司协办、爱思唯尔国际出版集团承办的“精彩案例我分享——关注糖尿病•聚焦GLP-1”案例征集活动将于2011年3月~ 11月在全国范围隆重展开。

关注青光眼患者， 让世界更明亮！
时间：2011-4~~2011-12
《中华眼科杂志》发起，辉瑞制药资助，旨在交流青光眼治疗理念，分享国内抗青光眼药物固定联合治疗经验的病例交流活动.

聚焦哮喘和COPD联合制剂治疗
时间：2010-12~~2011-12
哮喘和慢性阻塞性肺疾病（COPD）是常见、多发的气道炎症性疾病，这类疾病严重影响患者的生活质量。我们特别组织了该类案例征集活动，奖品丰厚，快来参与！

中国选择 达标看我
时间：2011-9~~2012-9
本次活动对典型病例以分享的形式总结临床经验，通过跨专科、多层次的学术交流，对降压治疗方案、疗效进行解析与点评。